QualityStocks would like to highlight Vasomedical, Inc. (
OTCBB: VASO), a global leader in non-invasive healthcare solutions and products. The company's proprietary core product line of Enhanced External Counterpulsation (EECP) Therapy systems is the leading product in the non-invasive treatment of cardiovascular disease. Vasomedical is the parent company of several operating subsidiaries - Vasomedical Solutions, Vasomedical Global, and VasoHealthcare. The company is pursuing a strategy of accretive acquisitions in the medical device and health care markets.
In the company’s news,
Vasomedical, a maker of medical devices and seller of diagnostic imaging products, reports that its EECP Therapy devices for the treatment of vascular endothelial dysfunction and for the prevention of onset and progression of cerebral, coronary, and peripheral vascular diseases will be featured at the Stony Brook Medicine’s new Center for Cardiovascular Wellness and Preventive Research.
EECP Therapy is an FDA-cleared, non-invasive therapeutic device manufactured by Vasomedical, designed to moderate the workload of the heart while increasing blood flow to the coronary arteries and other organs of the body. By focusing on this EECP Therapy, researchers at the new center will conduct research into cardiovascular health and seek to identify and develop new options to treat and prevent coronary artery disease, heart failure, and Alzheimer’s disease.
In addition, the center will be used to conduct exploratory research of the use of EECP Therapy as a means of preventing muscle soreness and injury in elite athletes.
Dr. Michael Poon, a professor of Emergency Medicine, Medicine (Cardiology), and Radiology, and Director of Advanced Cardiovascular Imaging at Stony Brook Medicine, will lead the research efforts.
“At Vasomedical, we have been proponents of EECP Therapy for almost 20 years, seeing incredible benefits to many different patient populations. Stony Brook University was among the first in the United States to adopt EECP Therapy as a noninvasive treatment for cardiac ailments and has participated in many published studies. We are grateful for Stony Brook University and Dr. Poon’s continued support and commitment to the research with our innovative devices,” Dr. John Hui, Chief Technology Officer of Vasomedical stated in the press release. “We look forward to seeing the results of their studies, and are pleased that such a reputable institution is working to raise public awareness and support a technology with the potential to revolutionize the cardiovascular health industry.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
